The Danish Medicines Agency (DMA) is warning consumers of the risk of liver dysfunction associated with voriconazole [Vf

  • PDF / 136,072 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 37 Downloads / 165 Views

DOWNLOAD

REPORT


1

■ The Danish Medicines Agency (DMA) is warning consumers of the risk of liver dysfunction associated with voriconazole [Vfend]. In this month’s Pharmacovigilance Update, the agency notes that there have been several cases of patients with altered liver function following treatment with Vfend. In rare cases, reactions have included hepatitis, cholestasis and liver failure. Prescribers are advised to monitor the liver function of patients undergoing Vfend treatment and seriously consider discontinuation of treatment if the patient develops any clinical indications or symptoms of voriconazole-induced liver damage. Vfend (Rm) and the risk of liver adverse reactions. Danish Pharmacovigilance 801108710 Update 1: 8, No. 8, 17 Jun 2010

0114-9954/10/1309-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved

Reactions 10 Jul 2010 No. 1309